CN112691079A - Foot bacteriostatic care solution containing traditional Chinese medicine extract and preparation method thereof - Google Patents
Foot bacteriostatic care solution containing traditional Chinese medicine extract and preparation method thereof Download PDFInfo
- Publication number
- CN112691079A CN112691079A CN202110108402.3A CN202110108402A CN112691079A CN 112691079 A CN112691079 A CN 112691079A CN 202110108402 A CN202110108402 A CN 202110108402A CN 112691079 A CN112691079 A CN 112691079A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- concentration
- foot
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003385 bacteriostatic effect Effects 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 239000000284 extract Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 238000000605 extraction Methods 0.000 title description 2
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 131
- 239000005017 polysaccharide Substances 0.000 claims abstract description 131
- 150000004676 glycans Chemical class 0.000 claims abstract description 118
- -1 glycyrrhiza polysaccharide Chemical class 0.000 claims abstract description 14
- 241000334160 Isatis Species 0.000 claims abstract description 13
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 13
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 13
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 12
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 12
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 10
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 10
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 7
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 13
- 241000180649 Panax notoginseng Species 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000010231 banlangen Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 241000233866 Fungi Species 0.000 abstract description 7
- 230000000740 bleeding effect Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000029663 wound healing Effects 0.000 abstract description 2
- 210000002683 foot Anatomy 0.000 description 63
- 239000000243 solution Substances 0.000 description 33
- 239000000843 powder Substances 0.000 description 25
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 241000191967 Staphylococcus aureus Species 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 206010067268 Post procedural infection Diseases 0.000 description 5
- 208000031650 Surgical Wound Infection Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 201000004647 tinea pedis Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000013460 sweaty Diseases 0.000 description 4
- 241000218202 Coptis Species 0.000 description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940124350 antibacterial drug Drugs 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000011477 liquorice Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010012504 Dermatophytosis Diseases 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 206010024774 Localised infection Diseases 0.000 description 2
- 241001460074 Microsporum distortum Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A foot bacteriostatic care solution containing traditional Chinese medicine extracts and a preparation method thereof relate to the field of foot care. The invention comprises the following steps: the concentration of the schisandra chinensis polysaccharide is 0.0027-0.3951 mg/mL; the concentration of the glossy privet fruit polysaccharide is 0.0032-0.44 mg/mL; the polysaccharide of the cassia seeds is 0.004-0.501 mg/mL; the concentration of the pseudo-ginseng polysaccharide is 0.00495-0.56 mg/mL; the concentration of the isatis root polysaccharide is 0.00441-0.4716 mg/mL; the concentration of the glycyrrhiza polysaccharide is 0.00414-0.654 mg/mL; the concentration of the coptis chinensis polysaccharide is 0.0131-0.961 mg/mL. The invention has the effects of resisting oxidation and bacteria, helping tissue structure regeneration and repair, promoting wound healing, stopping bleeding and the like, has obvious inhibiting effect on bacteria and fungi, and has obvious effect.
Description
Technical Field
The invention relates to the technical field of foot care, in particular to a foot bacteriostatic care solution containing traditional Chinese medicine extracts and a preparation method thereof.
Background
In the 21 st century, with the increasing frequency of life and the increasing living standard, people are continuously pursuing higher quality life. Although the living conditions gradually improve, the physical quality is continuously reduced, more attention is generally focused on regulating the heart and the like, and the importance of foot health to people is also ignored. The feet are kept warm for a long time in winter, so that the skin of the feet can sweat, cannot contact air, and is easy to infect bacteria and fungi.
Surgical Site Infection (SSI) is the most common postoperative infection in surgery. Including post-operative foot infections. It has been reported that about 1.9% of postoperative patients in the united states develop SSI, and that the incidence of SSI in developing countries may be higher in the second place of hospital-acquired infections in european SSI. The infection at the operation part not only affects the treatment effect and aggravates the economic burden of patients, but also brings devastating impact to the patients by serious patients, the infection at the operation part is positioned in the first three places of hospital infection in China, and the pathogenic bacteria mainly comprise gram-negative bacteria and gram-positive bacteria. Research shows that 58.04% of common pathogenic bacteria gram-negative bacteria infected at the orthopedic surgery part, wherein Escherichia coli is the main pathogen; the gram-positive bacteria account for 38.22 percent, and staphylococcus aureus is taken as the main bacteria; the fungi accounted for 3.74%. Infection is accompanied by the excessive application of clinical antibiotics, and drug-resistant pathogenic bacteria are commonly generated, so that the curative effect of the antibiotics is poor. Research shows that due to the non-standard use of antibacterial drugs, bacteria generally generate drug resistance to common clinical antibiotics, the drug resistance rate of staphylococcus aureus to penicillin reaches 98%, and the drug resistance rate of escherichia coli to piperacillin reaches 80%. Even bacteria with wide drug resistance and super bacteria appear, and great challenges are brought to the treatment and infection of human beings. The antibiotic and the disinfectant are two common antibacterial drugs at present, although the bacteriostatic and bactericidal mechanisms of the two antibacterial drugs are different, the bacteria can generate cross drug resistance to the disinfectant after resisting the antibiotic.
Currently, existing foot care solutions are primarily effective in removing cutin and preventing dry heel cracking, rarely act as a bacteriostatic and fungistatic agent, and may produce allergic reactions. Meanwhile, the existing foot care solution does not have the effects of preventing and treating foot postoperative infection, and the effect is not good enough.
Disclosure of Invention
The invention aims to provide a foot bacteriostatic care solution containing traditional Chinese medicine extracts and a preparation method thereof, and aims to solve the problems that the existing foot care solution cannot inhibit bacteria and fungi, possibly causes anaphylactic reaction, and cannot effectively prevent and treat foot postoperative infection.
The technical scheme adopted by the invention for solving the technical problem is as follows:
the invention relates to a foot bacteriostatic care solution containing traditional Chinese medicine extracts, which comprises the following components: fructus Schisandrae polysaccharide, fructus Ligustri Lucidi polysaccharide, semen Cassiae polysaccharide, Notoginseng radix polysaccharide, radix Isatidis polysaccharide, Glycyrrhrizae radix polysaccharide and Coptidis rhizoma polysaccharide.
As a preferred embodiment, the foot bacteriostatic care solution containing traditional Chinese medicine extracts comprises the following components:
the concentration of the schisandra chinensis polysaccharide is 0.0027-0.3951 mg/mL;
the concentration of the glossy privet fruit polysaccharide is 0.0032-0.44 mg/mL;
the polysaccharide of the cassia seeds is 0.004-0.501 mg/mL;
the concentration of the pseudo-ginseng polysaccharide is 0.00495-0.56 mg/mL;
the concentration of the isatis root polysaccharide is 0.00441-0.4716 mg/mL;
the concentration of the glycyrrhiza polysaccharide is 0.00414-0.654 mg/mL;
the concentration of the coptis chinensis polysaccharide is 0.0131-0.961 mg/mL.
As a preferred embodiment, the foot bacteriostatic care solution containing traditional Chinese medicine extracts comprises the following components:
schisandra chinensis polysaccharide with the concentration of 0.06102 mg/mL;
glossy privet fruit polysaccharide, the concentration is 0.08307 mg/mL;
the cassia seed polysaccharide with the concentration of 0.01836 mg/mL;
notoginseng polysaccharide, the concentration is 0.1647 mg/mL;
the concentration of the isatis root polysaccharide is 0.4716 mg/mL;
the concentration of the glycyrrhiza polysaccharide is 0.02853 mg/mL;
rhizoma Coptidis polysaccharide, concentration is 0.07281 mg/mL.
The invention has the beneficial effects that:
the invention optimizes a Chinese herbal medicine extract formula with antibacterial effect by using a uniform design method, which consists of schisandra chinensis polysaccharide, glossy privet fruit polysaccharide, cassia seed polysaccharide, pseudo-ginseng polysaccharide, isatis root polysaccharide, liquorice polysaccharide and coptis chinensis polysaccharide and is used for preventing foot infection and treating tinea pedis, dermatophytosis and the like. Although the 7 Chinese herbal medicines have antibacterial effects, the effect is weak when the Chinese herbal medicines are used alone, the antibacterial spectrum is narrow, and gram-positive bacteria, gram-negative bacteria and fungi are difficult to inhibit simultaneously. The invention prepares 7 Chinese herbal medicines into a formula, can improve the drug effect, broaden the antibacterial spectrum, can avoid the drug resistance of bacteria and fungi caused by single use, has the effects of resisting oxidation and bacteria, helping tissue structure regeneration and repair, promoting wound healing, stopping bleeding and the like, has obvious inhibiting effect on the bacteria and the fungi, and has obvious effect. The foot antibacterial care solution disclosed by the invention can be used for nursing foot operation wounds and normal feet, so that the microenvironment of the feet is improved, and the health level of the skin of the feet is improved.
The fructus Schisandrae extract mainly comprises lignanoid, volatile oil, polysaccharide, triterpene, organic acid, etc., wherein fructus Schisandrae polysaccharide has antibacterial activity, such as fructus Schisandrae Sphenantherae polysaccharide has antibacterial effect on Staphylococcus aureus. The active ingredients of fructus Ligustri Lucidi include salidroside, oleanolic acid, ursolic acid, and polysaccharide, etc., and the fructus Ligustri Lucidi polysaccharide has effects of resisting sepsis and resisting bacteria. The fructus Ligustri Lucidi leachate has antibacterial effect on Staphylococcus aureus, Staphylococcus albus, Pseudomonas aeruginosa, Bacillus proteus, Escherichia coli, Streptococcus A, and Streptococcus B. Fructus Ligustri Lucidi and fructus Schisandrae chinensis are often used in combination, and can inhibit bacteria at low concentration and kill bacteria at high concentration. The semen Cassiae comprises chemical components such as quinones, flavones, polysaccharides, alkaloids, etc., and has antibacterial effect. The semen Cassiae ethanol extractive solution and water extractive solution have different degrees of inhibiting effect on dermatophytes and bacteria. The parched semen Cassiae water decoction has effect in inhibiting Staphylococcus aureus. Notoginseng radix is rich in dencichine, saponin, polysaccharide and flavone. The Notoginseng radix water extract has effect in inhibiting Staphylococcus aureus. The radix Isatidis is rich in lignans, alkaloids, and polysaccharides. The radix Isatidis polysaccharide has effect of inhibiting Escherichia coli. The Glycyrrhrizae radix is rich in bioactive components such as polysaccharide, flavone, glycyrrhizic acid and its aglycone glycyrrhetinic acid. Although the glycyrrhiza polysaccharide has no obvious bacteriostatic activity, the glycyrrhiza polysaccharide has a better detoxification effect. The rhizoma Coptidis is rich in alkaloids, organic acids, polysaccharides, flavones, steroids, and volatile oils. The Coptidis rhizoma polysaccharide has inhibitory effect on Escherichia coli and Staphylococcus aureus.
Detailed Description
The foot antibacterial care solution is prepared from schisandra chinensis polysaccharide, glossy privet fruit polysaccharide, cassia seed polysaccharide, pseudo-ginseng polysaccharide, isatis root polysaccharide, liquorice polysaccharide and coptis chinensis polysaccharide, and the traditional Chinese medicine polysaccharides can make up for deficiencies of each other, so that the foot antibacterial care solution has an antibacterial effect, can effectively improve the state of foot skin such as foot odor, foot sweating, dermatophytosis and the like, is wide in application range, free of anaphylactic reaction and other adverse reactions and remarkable in effect; meanwhile, the foot postoperative infection can be effectively prevented and treated.
The invention relates to a foot bacteriostatic care solution containing traditional Chinese medicine extracts, which comprises the following components: fructus Schisandrae polysaccharide, fructus Ligustri Lucidi polysaccharide, semen Cassiae polysaccharide, Notoginseng radix polysaccharide, radix Isatidis polysaccharide, Glycyrrhrizae radix polysaccharide and Coptidis rhizoma polysaccharide.
Preferably, the foot bacteriostatic care solution containing the traditional Chinese medicine extract comprises the following components:
the concentration of the schisandra chinensis polysaccharide is 0.0027-0.3951 mg/mL;
the concentration of the glossy privet fruit polysaccharide is 0.0032-0.44 mg/mL;
the polysaccharide of the cassia seeds is 0.004-0.501 mg/mL;
the concentration of the pseudo-ginseng polysaccharide is 0.00495-0.56 mg/mL;
the concentration of the isatis root polysaccharide is 0.00441-0.4716 mg/mL;
the concentration of the glycyrrhiza polysaccharide is 0.00414-0.654 mg/mL;
the concentration of the coptis chinensis polysaccharide is 0.0131-0.961 mg/mL.
More preferably, the foot bacteriostatic care solution containing the traditional Chinese medicine extract comprises the following components:
schisandra chinensis polysaccharide with the concentration of 0.06102 mg/mL;
glossy privet fruit polysaccharide, the concentration is 0.08307 mg/mL;
the cassia seed polysaccharide with the concentration of 0.01836 mg/mL;
notoginseng polysaccharide, the concentration is 0.1647 mg/mL;
the concentration of the isatis root polysaccharide is 0.4716 mg/mL;
the concentration of the glycyrrhiza polysaccharide is 0.02853 mg/mL;
rhizoma Coptidis polysaccharide, concentration is 0.07281 mg/mL.
The invention relates to a preparation method of a foot bacteriostatic care solution containing traditional Chinese medicine extracts, which comprises the following steps:
(1) grinding fructus Schisandrae chinensis, fructus Ligustri Lucidi, semen Cassiae, Notoginseng radix, radix Isatidis, Glycyrrhrizae radix, and Coptidis rhizoma into coarse powder respectively; weighing 50g of fructus schizandrae coarse powder, adding distilled water, soaking for 24h, heating and boiling for 1h, filtering the liquid medicine, repeatedly decocting for 3 times, combining the filtrates, concentrating to about 30mL, adding 2 times volume of 60% ethanol for alcohol precipitation, filtering, adding water to dissolve the precipitate, removing ethanol by a rotary evaporator, freeze-drying in a freeze dryer to obtain fructus schizandrae powder; the content of the polysaccharides in the schisandra chinensis powder is measured by a colorimetric method, and the amount of the schisandra chinensis polysaccharides in 1g of schisandra chinensis powder is about 50.00-90.23 mg.
(2) Respectively pulverizing fructus Ligustri Lucidi, semen Cassiae, Notoginseng radix, radix Isatidis, Glycyrrhrizae radix, and Coptidis rhizoma into powder; the content of polysaccharides in the glossy privet fruit powder, the cassia seed powder, the pseudo-ginseng powder, the isatis root powder, the licorice powder and the coptis powder is measured by a colorimetric method, wherein the content of the polysaccharides in 1g of the glossy privet fruit powder is 5.58-8.03 mg, the content of the polysaccharides in 1g of the cassia seed powder is 5.88-10.74 mg, the content of the pseudo-ginseng polysaccharides in 1g of the pseudo-ginseng powder is 12.70-21.00 mg, the content of the isatis root polysaccharides in 1g of the isatis root powder is 6.51-10.42 mg, the content of the glycyrrhiza polysaccharides in 1g of the licorice powder is 7.34-8.31 mg, and the content of the coptis polysaccharides in 1g of the coptis powder is 0.32-36.25 mg.
(3) Preparing the prepared traditional Chinese medicine powder into a solution according to the dosage ratio, and obtaining the foot bacteriostatic care solution.
The foot bacteriostatic care solution containing the traditional Chinese medicine extract can be applied to uniformly cover the skin of the foot by smearing or spraying, is convenient to operate, can play a role in bacteriostasis while caring the foot, and can effectively prevent postoperative infection of the foot.
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
1. Grinding fructus Schisandrae chinensis, fructus Ligustri Lucidi, semen Cassiae, Notoginseng radix, radix Isatidis, Glycyrrhrizae radix, and Coptidis rhizoma into coarse powder respectively; weighing 50g of fructus schizandrae coarse powder, adding an appropriate amount of distilled water (submerging the Chinese medicinal coarse powder), soaking for 24h, heating and boiling for 1h, filtering the liquid medicine, repeatedly decocting for 3 times, combining the filtrates, concentrating to about 30mL, adding 2 times volume of 60% ethanol for alcohol precipitation, filtering, adding water to dissolve the precipitate, removing ethanol with a rotary evaporator, and freeze-drying in a freeze dryer to obtain fructus schizandrae powder. Respectively pulverizing fructus Ligustri Lucidi, semen Cassiae, Notoginseng radix, radix Isatidis, Glycyrrhrizae radix, and Coptidis rhizoma into powder.
2. Preparation of a sheet of polysaccharide-containing filter paper
Preparing the prepared traditional Chinese medicine powder into polysaccharide solution according to the proportion in the table 1, filtering the polysaccharide solution by using a Millex-Cp (pore diameter is 0.22 mu m) filter, sucking the polysaccharide solution by using a pipette, slowly dropping the polysaccharide solution on a sterilized filter paper wafer with the diameter of 6mm, and airing to prepare a filter paper sheet containing polysaccharide.
3. Preparation of staphylococcus aureus liquid and escherichia coli liquid
Taking a strain stored in a refrigerator, inoculating the strain on a solid culture medium (3 g of beef extract, 10g of peptone, 5g of NaCl, 20g of agar and 1000mL of distilled water by using a plate line drawing method, adjusting the pH to 7.6, and carrying out autoclaving at 121 ℃ for 30min for later use), culturing for 24h, selecting a single colony, inoculating the single colony in a slant culture medium (200 g of potato, mixing the potato and the water according to the mass ratio of 2:10, heating and boiling at 80 ℃ for 30min, adding 15-20 g of sucrose, 20-30 g of agar, fixing the volume to 1000mL of distilled water, keeping the pH value to 7.4, and carrying out autoclaving at 121 ℃ for 30min for later use), and culturing for 24h at 37 ℃. 10mL of the prepared liquid culture medium is taken, and bacteria on the inclined plane are eluted to obtain bacterial liquid. Sequentially diluting the bacterial liquid into 3 concentrations by 10 times, respectively sucking 0.1mL from each concentration by using a pipette, coating the bacterial liquid on a corresponding culture medium for three times, standing for 24h, then counting plate bacterial colonies, taking the average value of the three times, and calculating the concentration of the bacterial liquid; finally, the bacterial liquid is diluted to (1X 10) by using a culture medium6)CFU/mL。
4. Preparation of the plates
Sucking 1mL of the bacterial liquid, transferring the bacterial liquid into a test tube filled with 9mL of sterile physiological saline to prepare 10mL of bacterial suspension with the concentration of 25 mu g/mL, sucking 0.2mL of the bacterial suspension, adding the bacterial suspension into a culture dish with the thickness of 90mm, pouring 15mL of nutrient agar (45 ℃) into the culture dish, and uniformly mixing the culture medium and the bacterial liquid. The prepared filter paper containing the polysaccharide is placed in the center of a culture dish, the culture is carried out for 24 hours at the temperature of 37 ℃, three parallel experiments are carried out, meanwhile, the culture dish without the filter paper is used as a blank control group, and the diameter of the bacteriostatic ring is measured by a cross method.
5. Design of uniform design method
On the premise of consistent raw material source, grinding conditions, constant volume and other conditions, determining the main factors and levels of investigation. According to the results of preliminary experiments, fructus Schisandrae polysaccharide, fructus Ligustri Lucidi polysaccharide, semen Cassiae polysaccharide, Notoginseng radix polysaccharide, radix Isatidis polysaccharide, and Glycyrrhrizae radix are respectively changedThe usage amount of polysaccharide and rhizoma Coptidis polysaccharide is selected, the influence of the polysaccharide on antibacterial effect of Staphylococcus aureus is examined, and U is selected31(317) The table arrangement experiment was designed uniformly. Each experiment was repeated 3 times. The measurement results are shown in Table 1.
TABLE 1
According to U31(317) The optimal formula for optimizing the uniform design table is as follows: 0.06102mg/mL of schisandra chinensis polysaccharide, 0.08307mg/mL of glossy privet fruit polysaccharide, 0.01836mg/mL of cassia seed polysaccharide, 0.1647mg/mL of pseudo-ginseng polysaccharide, 0.4716mg/mL of isatis root polysaccharide, 0.02853mg/mL of liquorice polysaccharide and 0.07281mg/mL of coptis chinensis polysaccharide, and under the condition, the optimal diameter of the bacteriostatic ring for staphylococcus aureus is (7.57 +/-0.19) mm.
6. Process verification test
Under the best scheme, 3 parallel samples are extracted, and the diameter of the bacteriostatic ring is measured. The diameter of the bacteriostatic ring of the formula for staphylococcus aureus is (7.65 +/-0.15) mm.
7. Inhibitory Effect of polysaccharides on Escherichia coli
Taking the optimal formula, and measuring the inhibition effect of the optimal formula on escherichia coli. The diameter of the bacteriostatic ring of the formula to escherichia coli is (8.35 +/-0.17) mm.
Clinical case 1
Tanxax, male, 22 years old, chapped foot with long-term sweaty foot and foot odor, starting to use the foot care solution prepared in the embodiment 1 in 3 months and 9 months in 2020, spraying the foot care solution on the foot 2-5 mL each time after the foot is washed and dried. After continuous use for two weeks, the feet are smooth and tender, and the sweaty feet and the foot odor are relieved.
Clinical case 2
Plum xxx, female, 43 years old, with chronic tinea pedis, the foot care solution prepared in the embodiment 2 is applied on 12 months and 9 months in 2020, and after washing, the foot is sprayed on the foot, and 2-5 mL of the foot care solution is sprayed each time. After continuous use for two weeks, the sweaty feet and the tinea pedis are basically cured.
Clinical case 3
183 foot skin patients were selected for clinical trials.
The treatment method is twice daily. The foot cream is smeared or sprayed on feet, 2-5 mL of the foot cream is sprayed each time, and one week is a treatment course.
The cure means to cure the skin disease completely, the effective means that the clinical symptoms are obviously improved, the ineffective means that the clinical symptoms are not changed, and the observation result is shown in table 2.
TABLE 2
| Item | Cure/human | Effective/human | Invalid/human | Total effective rate |
| Sweaty feet and smelly feet | 50 | 16 | 0 | 100％ |
| Tinea pedis | 13 | 40 | 3 | 94.64％ |
| Chapped foot | 24 | 35 | 2 | 96.72％ |
The observation results of 183 foot skin patients show that the foot care solution has obvious curative effects on foot odor, foot sweat, tinea pedis and foot rhagadia, and no adverse reaction is found in clinical observation, so that the foot care solution has the characteristics of safety and effectiveness.
The invention discloses a foot bacteriostatic care solution containing traditional Chinese medicine extracts, which can be realized by appropriately improving process parameters by referring to the contents in the field. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the invention has been described in terms of preferred embodiments, it will be apparent to those skilled in the art that the technology can be practiced and applied by modifying or appropriately combining the products described herein without departing from the spirit and scope of the invention.
Claims (3)
1. A foot bacteriostatic care solution containing traditional Chinese medicine extracts is characterized by comprising the following components: fructus Schisandrae polysaccharide, fructus Ligustri Lucidi polysaccharide, semen Cassiae polysaccharide, Notoginseng radix polysaccharide, radix Isatidis polysaccharide, Glycyrrhrizae radix polysaccharide and Coptidis rhizoma polysaccharide.
2. The foot bacteriostatic care solution containing the traditional Chinese medicine extract as claimed in claim 1, which is characterized by comprising the following components in percentage by weight:
the concentration of the schisandra chinensis polysaccharide is 0.0027-0.3951 mg/mL;
the concentration of the glossy privet fruit polysaccharide is 0.0032-0.44 mg/mL;
the polysaccharide of the cassia seeds is 0.004-0.501 mg/mL;
the concentration of the pseudo-ginseng polysaccharide is 0.00495-0.56 mg/mL;
the concentration of the isatis root polysaccharide is 0.00441-0.4716 mg/mL;
the concentration of the glycyrrhiza polysaccharide is 0.00414-0.654 mg/mL;
the concentration of the coptis chinensis polysaccharide is 0.0131-0.961 mg/mL.
3. The foot bacteriostatic care solution containing the traditional Chinese medicine extract as claimed in claim 2, which is characterized by comprising the following components in percentage by weight:
schisandra chinensis polysaccharide with the concentration of 0.06102 mg/mL;
glossy privet fruit polysaccharide, the concentration is 0.08307 mg/mL;
the cassia seed polysaccharide with the concentration of 0.01836 mg/mL;
notoginseng polysaccharide, the concentration is 0.1647 mg/mL;
the concentration of the isatis root polysaccharide is 0.4716 mg/mL;
the concentration of the glycyrrhiza polysaccharide is 0.02853 mg/mL;
rhizoma Coptidis polysaccharide, concentration is 0.07281 mg/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110108402.3A CN112691079A (en) | 2021-01-27 | 2021-01-27 | Foot bacteriostatic care solution containing traditional Chinese medicine extract and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110108402.3A CN112691079A (en) | 2021-01-27 | 2021-01-27 | Foot bacteriostatic care solution containing traditional Chinese medicine extract and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112691079A true CN112691079A (en) | 2021-04-23 |
Family
ID=75516220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110108402.3A Pending CN112691079A (en) | 2021-01-27 | 2021-01-27 | Foot bacteriostatic care solution containing traditional Chinese medicine extract and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112691079A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110882277A (en) * | 2018-08-16 | 2020-03-17 | 安徽世龙生物医药科技有限公司 | Lotion for inhibiting foot sweat and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN87102282A (en) * | 1987-03-21 | 1988-10-12 | 唐正发 | The production method of eczema medicine |
| RU2071343C1 (en) * | 1993-02-26 | 1997-01-10 | Научно-исследовательский институт фармакологии Томского научного центра РАМН | Method of preparing substance showing antiulcer activity and pharmaceutical composition based on thereof |
| CN101461763A (en) * | 2008-12-30 | 2009-06-24 | 昆明圣火药业（集团）有限公司 | Method for producing cosmetics containing notoginseng polysaccharide and use |
| CN101933966A (en) * | 2010-08-31 | 2011-01-05 | 南京中医药大学 | Active site composition of isatis roots, as well as preparation method and application thereof |
| CN107496662A (en) * | 2017-09-19 | 2017-12-22 | 界首市菁华科技信息咨询服务有限公司 | A kind of medicament for treating tinea pedis and preparation method thereof |
| CN111202799A (en) * | 2020-02-14 | 2020-05-29 | 张秀燕 | Wound nursing spray |
| CN111467402A (en) * | 2020-05-13 | 2020-07-31 | 黄敏 | Antibacterial traditional Chinese medicine extracting solution and preparation method and application thereof |
| CN112089653A (en) * | 2020-08-20 | 2020-12-18 | 北京工商大学 | Compound traditional Chinese medicine bacteriostatic agent and application thereof |
-
2021
- 2021-01-27 CN CN202110108402.3A patent/CN112691079A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN87102282A (en) * | 1987-03-21 | 1988-10-12 | 唐正发 | The production method of eczema medicine |
| RU2071343C1 (en) * | 1993-02-26 | 1997-01-10 | Научно-исследовательский институт фармакологии Томского научного центра РАМН | Method of preparing substance showing antiulcer activity and pharmaceutical composition based on thereof |
| CN101461763A (en) * | 2008-12-30 | 2009-06-24 | 昆明圣火药业（集团）有限公司 | Method for producing cosmetics containing notoginseng polysaccharide and use |
| CN101933966A (en) * | 2010-08-31 | 2011-01-05 | 南京中医药大学 | Active site composition of isatis roots, as well as preparation method and application thereof |
| CN107496662A (en) * | 2017-09-19 | 2017-12-22 | 界首市菁华科技信息咨询服务有限公司 | A kind of medicament for treating tinea pedis and preparation method thereof |
| CN111202799A (en) * | 2020-02-14 | 2020-05-29 | 张秀燕 | Wound nursing spray |
| CN111467402A (en) * | 2020-05-13 | 2020-07-31 | 黄敏 | Antibacterial traditional Chinese medicine extracting solution and preparation method and application thereof |
| CN112089653A (en) * | 2020-08-20 | 2020-12-18 | 北京工商大学 | Compound traditional Chinese medicine bacteriostatic agent and application thereof |
Non-Patent Citations (8)
| Title |
|---|
| 刘平平: "三七发酵液多糖抗衰老活性研究", 《日用化学工业》 * |
| 刘朋月: "决明子多糖的研究进展", 《食品研究与开发》 * |
| 李立: "板蓝根颗粒的研究概况", 《中国民族民间医药》 * |
| 范荣车: "不同溶剂提取五味子多糖体外生物活性研究", 《中成药》 * |
| 蔡毅东编: "《古代经典名方从书 半夏泻心汤》", 30 September 2019, 中国中医药出版社 * |
| 谢川东: "黄连抗菌活性成分研究", 《湖北农业科技》 * |
| 金岚: "《新编中药药理与临床应用》", 31 May 1995, 上海科学技术出版社 * |
| 陈明岭: "《皮肤常用中药药理及临床》", 31 October 2017, 中国科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110882277A (en) * | 2018-08-16 | 2020-03-17 | 安徽世龙生物医药科技有限公司 | Lotion for inhibiting foot sweat and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109568206B (en) | Special antibacterial composition and lotion for women and preparation method thereof | |
| CN111202822A (en) | Gynecological external antibacterial spray and preparation method thereof | |
| CN103110868B (en) | Skin care solution and preparation method thereof | |
| CN106900781A (en) | Antibacterial bacteriostatic liquid prepared by a kind of vegetable Chinese herbal medicine | |
| CN105123816A (en) | Sterilizing and disinfecting liquid for clinical laboratory and preparation method | |
| CN107029210A (en) | Wood frog's fallopian tube antibacterial peptide oral spray | |
| US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
| CN112691079A (en) | Foot bacteriostatic care solution containing traditional Chinese medicine extract and preparation method thereof | |
| CN106491415A (en) | A kind of pox-eliminating whitening concealer and preparation method thereof | |
| CN104666594B (en) | It is a kind of to treat tinea pedis moxibustion item and preparation method thereof | |
| CN106620633A (en) | Skin repairing cream for tumor patients and preparation method of skin repairing cream | |
| CN114224952B (en) | Traditional Chinese medicine decontamination preparation for soothing skin of infants and preparation method thereof | |
| CN108403570A (en) | There are the body condensation and preparation method of improvement to pruitus caused by eczema | |
| CN1330344C (en) | Medicinal composition for treating acute, chronic pharyngolaryngitis and its preparation method | |
| CN109646546B (en) | A Chinese medicinal composition for preventing and treating diarrhea of livestock, and its preparation method | |
| CN102145072A (en) | Traditional Chinese medicine composition for treating infantile eczema and dermatitis skin diseases | |
| Xu et al. | Application of Atractylodes Macrocephala Koidz Extract in Methicillin-Resistant Staphylococcus Aureus | |
| CN111588767A (en) | Grapefruit seed gynecological gel | |
| CN105079305A (en) | Antisepsis and anti-inflammation external traditional Chinese medicine compound gel and preparation method thereof | |
| CN104304352A (en) | Traditional Chinese medicament used for air disinfection of operating room and preparation method of traditional Chinese medicament | |
| CN1970020B (en) | A pharmaceutical composition, preparation process and application thereof | |
| CN114010677B (en) | Pharmaceutical composition for treating tinea versicolor | |
| CN106389280A (en) | Special moisturizing spray used for acne skins, and production method thereof | |
| CN114392310B (en) | Anti-inflammatory antipruritic skin-moistening traditional Chinese medicine external preparation and preparation method and application thereof | |
| CN108685821B (en) | Traditional Chinese medicine composition with effect of enhancing skin tolerance and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210423 |